Publications by authors named "Peiji Dai"
Objective: To evaluate whether the intense simplified strategy, which comprises short term intensive insulin therapy (SIIT) followed by subsequent oral antihyperglycaemic regimens, could improve long term glycaemic outcomes in patients with newly diagnosed type 2 diabetes mellitus and severe hyperglycaemia.
Design: Multicentre, open label, randomised trial.
Setting: 15 hospitals in China between December 2017 and December 2020.
Background: This study aims to investigate the changes in circulating dipeptidyl peptidase-4 (DPP-4) activity following short-term intensive insulin therapy (SIIT) in newly diagnosed type 2 diabetes (T2D) patients and to assess its potential in predicting long-term remission.
Methods: Ninety-five patients underwent SIIT for 2-3 weeks to attain and sustain near-normal glycemia. Insulin was then discontinued, and patients were followed for a year to evaluate glycemic outcomes.
Background: Extrachromosomal circular DNA (eccDNA) has emerged as a promising biomarker for disease diagnosis and prognosis prediction. However, its role in type 2 diabetes remains unexplored.
Objective: To investigate the characteristics and dynamics of circulating eccDNAs in newly diagnosed type 2 diabetes mellitus (T2DM) patients undergoing short-term intensive insulin therapy (SIIT), a highly effective treatment for inducing long-term glycemic remission.
Article Synopsis
- The study investigates how short-term intensive insulin therapy affects inflammatory cytokines in newly diagnosed type 2 diabetes patients, noting that diabetes is a chronic inflammatory disease.
- Thirty-three patients participated, undergoing tests on 40 inflammatory cytokines before and after one week of continuous subcutaneous insulin infusion (CSII) therapy, along with pathway analysis.
- Results showed that five cytokines significantly decreased post-therapy, with additional findings revealing differences based on baseline glycated hemoglobin (HbA1c) levels; the changes were related to the TNF signaling pathway, particularly with NF-κB activation in patients with higher HbA1c.